MNPR Monopar Therapeutics Inc.
USHealthcareAs of 2026-07-09 16:00
Why MNPR matters now
Monopar Therapeutics Inc. (MNPR) is a US stock in Healthcare. The latest InvestLog snapshot shows $104.50 with +5.27% on the session and $700.1M in market capitalization; recent performance reads 1-month +22.23% and YTD +3.32%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.9M, and EPS of $-0.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.2%.
The latest indexable market news headline is "Monopar Therapeutics: ALXN1840's Bull Case Has Improved" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $110.00; recent insider activity includes Cittadine Andrew filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.25
P/S
0.00
EV/EBITDA
-25.55
DCF Value
$7.99
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-12.8%
ROA
-10.9%
ROIC
-13.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.9M | $-0.46 |
| Q4 2025 | $0.00 | $-5.2M | $-0.78 |
| FY 2025 | $0.00 | $-13.7M | $-1.85 |
| Q3 2025 | $0.00 | $-3.4M | $-0.48 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$110.00
Target (Median)
$110.00
Target Range
$105.00 - $115.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.54
Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Validive, a specialized clonidine hydrochloride mucobuccal tablet, is currently undergoing Phase 2b/3 clinical trials. This therapy aims to prevent severe oral mucositis, a debilitating side effect of chemoradiotherapy, in patients suffering from oropharyngeal cancer. The company's pipeline also includes Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for advanced soft tissue sarcoma. Furthermore, Monopar is developing MNPR-101, an antibody engineered to target the urokinase plasminogen activator receptor (uPAR) for various cancer indications. A radioimmunotherapeutic variant of MNPR-101, named MNPR-101 RIT, is being explored for its potential in both cancer therapy and the treatment of severe COVID-19. Another promising compound, MNPR-202, an analog of camsirubicin, is being developed to potentially address cancers that have developed resistance to doxorubicin and camsirubicin. Monopar Therapeutics Inc. maintains strategic partnerships, including one with the Grupo Español de Investigación en Sarcomas (GEIS) for the advancement of camsirubicin in patients with advanced soft tissue sarcoma. They also collaborate with NorthStar Medical Radioisotopes, LLC on the development of radio-immunotherapeutics targeting severe COVID-19, and with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related compounds across different cancer types. The company was established in 2014 and its corporate headquarters are situated in Wilmette, Illinois.